EpiEndo publishes new data supporting glasmacinal’s potential in COPD
Ella Day | June 13, 2025 | News story | Medical Communications, Research and Development | Chronic Diseases, EpiEndo Pharmaceuticals, Fraunhofer Institute for Toxicology and Experimental Medicine, antimicrobial resistance, chronic obstructive pulmonary disease (COPD), lung disease
EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of its lead asset, EP395 (glasmacinal), as an oral treatment for chronic obstructive pulmonary disease (COPD).
The published data includes findings from both clinical and preclinical studies. A clinical study conducted in collaboration with the Fraunhofer Institute for Toxicology and Experimental Medicine, Germany, showed that glasmacinal enhanced host defence responses to inhaled lipopolysaccharide in healthy volunteers, while reducing pro-inflammatory mediators.
Two additional preclinical studies demonstrated glasmacinal’s strong anti-inflammatory effect in neutrophilic airway inflammation – comparable to that of azithromycin, a commonly used but antibiotic-based treatment. Notably, glasmacinal achieved this without exhibiting antimicrobial activity, a key advantage in avoiding antimicrobial resistance.
A third paper confirmed that glasmacinal not only has minimal antibacterial activity but also improves the barrier function of the respiratory epithelium.
“These findings support our hypothesis that glasmacinal could be effective in reducing COPD exacerbations while avoiding the risks associated with long-term antibiotic use,” said Maria Bech, CEO of EpiEndo.
Clive Page, chair of EpiEndo’s scientific advisory board, added that the data reflects broad anti-inflammatory potential, reinforcing glasmacinal’s relevance across different types of airway inflammation.
COPD refers to a group of lung conditions, including emphysema and chronic bronchitis, which cause breathing difficulties. It affects over 390 million people globally and is a leading cause of death worldwide.
Ella Day
13/6/25
Related Content
Glox Therapeutics Awarded £1M PACE Grant to Accelerate Development of Precision Antibiotics Against Antimicrobial-resistant Pathogens
Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and …
European Parliament shares goal to tackle antimicrobial resistance
The European Parliament has shared its recommendations for a “coordinated EU response to health threats …
Bellerophon Therapeutics completes phase 3 study for fibrotic interstitial lung disease drug
US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed …
